New therapeutic perspectives in CCDC6 deficient lung cancer cells

International Journal of Cancer

Volumn 136, Issue 9, 2015, Pages 2146-2157

  Morra, Francesco ^a,b   Luise, Chiara ^a   Visconti, Roberta ^a   Staibano, Stefania ^b   Merolla, Francesco ^b   Ilardi, Gennaro ^b   Guggino, Gianluca ^c   Paladino, Simona ^b   Sarnataro, Daniela ^b,d   Franco, Renato ^e   Monaco, Roberto ^c   Zitomarino, Federica ^e   Pacelli, Roberto ^b   Monaco, Guglielmo ^c   Rocco, Gaetano ^e   Cerrato, Aniello ^a   Linardopoulos, Spiros ^f   Muller, Mark T ^g   Celetti, Angela ^a  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CARDARELLI HOSPITAL   (Italy)

^d CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^e Institute G Pascale   (Italy)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Candidate biomarker; CCDC6; DNA damage and homologousdirected repair; NSCLC; Resistance to platinum salts and PARP 1 inhibitor sensitivity

Indexed keywords

CISPLATIN; COILED COIL DOMAIN CONTAINING 6 PROTEIN; OLAPARIB; RAD51 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CCDC6 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; FEMALE; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER CELL LINE; LYMPH NODE METASTASIS; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; TISSUE MICROARRAY; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; DEFICIENCY; DRUG EFFECTS; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; CYTOSKELETAL PROTEINS; DISEASE-FREE SURVIVAL; DNA DAMAGE; DNA REPAIR; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PHTHALAZINES; PIPERAZINES; RAD51 RECOMBINASE;

EID: 84923212201     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29263     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin 2009;59: 225-49.
2. Andre F, McShane LM, Michiels S, et al. Biomarker studies: A call for a comprehensive biomarker study registry. Nat Rev Clin Oncol 2011;8: 171-6.
3. Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 2012; 12: 801-17.
4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350: 2129-39.
5. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALKpositive non-small-cell lung cancer: Up dated results from a phase 1 study. Lancet Oncol 2012; 13: 1011-9.
6. Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-Tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 2013;340: 97-103.
7. Zeng-Rong N, Paterson J, Alpert L, et al. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res 1995;55: 4760-4.
8. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002;94: 1091-9.
9. Duchesne GM. Fundamental bases of combined therapy in lung cancer: Cell resistance to chemotherapy and radiotherapy. Lung Cancer 1994;10: S67-S72.
10. Guo WF, Lin RX, Huang J, et al. Identification of differentially expressed genes contributing to radioresistance in lung cancer cells using microarray analysis. Radiat Res 2005;164: 27-35.
11. De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. The elephant and the blind men: Making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol 2013; 3: 228.
12. Ashworth A. A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008;26: 3785-90.
13. Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005;52: 25-33.
14. Oplustilova L, Wolanin K, Mistrik M, et al. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle 2012;11: 3837-50.
15. Postel-Vinay S, Bajrami I, Friboulet L, et al. A high-Throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene 2013;32: 5377-87.
16. Celetti A, Cerrato A, Merolla F, et al. H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: Functional characterization. Oncogene 2004;23: 109-21.
17. Merolla F, Pentimalli F, Pacelli R, et al. Involvement of H4(D10S170) protein in ATMdependent response to DNA damage. Oncogene 2007;26: 6167-75.
18. Merolla F, Luise C, Muller MT, et al. Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage. PLos ONE 2012;7: E36177.
19. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the RET protooncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990; 60: 557-63.
20. Drechsler M, Hildebrandt B, Kündgen A, et al. Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-Term responsiveness to imatinib. Ann Hematol 2007;86: 353-4.
21. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18: 378-81.
22. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150: 1107-20.
23. Matsubara D, Kanai Y, Ishikawa S, et al. Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad. J Thorac Oncol 2012;7: 1872-6.
24. Chou TC, Talaly P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 1977;252: 6438-42.
25. Jasin M. Genetic manipulation of genomes with rare-cutting endonucleases. Trends Genet 1996;12: 224-8.
26. Staibano S, Ilardi G, Leone V, et al. Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors. BMC Cancer 2013;13: 433-44.
27. Tutt A, Bertwistle D, Valentine J, et al. Mutation in Brca2 stimulates error-prone homologydirected repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 2001;20: 4704-16.
28. Mao Z, Bozzella M, Seluanov A, Gorbunova V. Comparison of nonhomologous end joining and homologous recombination in human cells. DNA Repair (Amst) 2008;10: 1765-71.
29. Edge SB, Byrd DR, Compton CC, et al, eds. AJCC cancer staging manual, 7th ed. New York: Springer, 2010. 253-70.
30. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434: 917-21.
31. Cuozzo C, Porcellini A, Angrisano T, et al. DNA damage, homology-directed repair, and DNA methylation. PLoS Genet 2007;3: E110.
32. Lee B, Kim J, Taylor M, Muller MT. DNA methyltransferase 1-Associated protein (DMAP1) is a co-repressor that stimulates DNA methylation globally and locally at sites of double strand DNA break repair. J Biol Chem 2010;285: 37630-40.
33. Lee B, Morano A, Porcellini A, Muller MT. GADD45a inhibition of DNMT1 dependent DNA methylation during homology directed DNA repair. Nucleic Acids Res 2011;40: 2481-93.
34. Morano A, Angrisano T, Russo G, et al. Targeted DNA methylation by homology-directed repair in mammalian cells. Transcription reshapes methylation of the repaired gene. Nucleic Acids Res 2014;42: 804-21.
35. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008;105: 17079-84.
36. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361: 123-34.
37. Tutt A, Robson M, Garber JE, et al. Oral poly(-ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 2010;376: 235-44.
38. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2012;71: 3-10.
39. Birkelbach M, Ferraiolo N, Gheorghiu L, et al. Detection of impaired homologous recombination repair in NSCLC cells and tissues. J Thorac Oncol 2013;8: 279-86.
40. Cheng H, Zhang Z, Borczuk A, et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis 2013;34: 739-49.
41. Gridelli C, Rossi A, Di Maio M, et al. Rationale and design of MILES-3 and MILES-4 studies: Two randomized phase 3 trials comparing singleagent chemotherapy versus cisplatin-based doublets in elderly patients with advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer 2014; 15: 166-70.
42. Bowden NA. Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy? Cancer Lett 2014;346: 163-71.
43. Lord CJ, McDonald S, Swift S, et al. A highthroughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 2008;7: 2010-9.
44. Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: A phase 1 doseescalation trial. Lancet Oncol 2013;14: 882-92.
45. Zhao J, Tang J, Men W, Ren K. FBXW7-mediated degradation of CCDC6 is impaired by ATM during DNA damage response in lung cancer cells FEBS 2012;586: 4257-63.
46. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell 2009;138: 389-403.
47. Leone V, Mansueto G, Pierantoni GM, et al. CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1. Oncogene 2010;29: 4341-51.
48. Jeannot V, Busser B, Brambilla E, et al. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism. Int J Cancer 2014;134: 2560-71.
49. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;13: 1160-74.
50. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366: 883-92.